19:11 ETRobbins LLP Urges SPRY Stockholders Who Lost Money Investing in ARS Pharmaceuticals Inc. to Contact the Firm for Information About Leading the Class Action Lawsuitprnewswire·16 hours agoSPRY+4.01%
ARS Pharmaceuticals Chief Commercial Officer Margaret Ekins Smith files initial beneficial ownership statementPUBT·19 hours agoSPRY+4.01%
20:01 ETSPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuitprnewswire·1 day ago, 07:01 PMSPRY+4.01%CVS+0.31%
Swarmer Posts Downbeat Q2 Results, Joins TSS, ARS Pharmaceuticals, Globant And Other Big Stocks Moving Lower In Friday’s Pre-Market Sessionbenzinga_article·Aug 14 at 07:06 AMMESO-1.70%GLOB+0.08%
ARS Pharmaceuticals Reports Q2 2026 Results: Full Earnings Call Transcriptbenzinga_article·Aug 13 at 04:17 PMSPRY+4.01%
ARS Pharmaceuticals drops on abandoning DTC neffy marketing, Q2 EPS missMSN·Aug 13 at 04:14 PMSPRY+4.01%
12 Health Care Stocks Moving In Thursday's After-Market Sessionbenzinga_article·Aug 13 at 04:06 PMMDXH-4.34%CAPR-8.19%
ARS Pharmaceuticals | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 33.66 MEarnings Watch·Aug 13 at 03:11 PMSPRY+4.01%
ARS Pharma Q2 FY26 net loss widens to $62.34 million; revenue rises 114.11% to $33.66 millionPUBT·Aug 13 at 03:02 PMSPRY+4.01%
SPRY Deadline Alert: SueWallSt Reminds ARS Pharmaceuticals Inc. (SPRY) Investors of Securities Class Action Deadline on October 5, 2026PR Newswire·Aug 13 at 11:37 AMSPRY+4.01%
